A Nature Communications study linked post-cancer biomarker trajectories—including metabolic and inflammatory markers—to later cardiovascular disease (CVD) risk. The report describes how biomarker changes after cancer diagnosis can map to differential cardiovascular outcomes, shifting how clinicians may monitor competing disease processes. The work was framed as an expanded view of cardio-oncology risk assessment, tracking trajectories rather than single time-point measurements. By tying dynamic biomarker patterns to CVD, the study supports more granular risk stratification after cancer. For industry, the finding strengthens the rationale for longitudinal biomarker programs in clinical trials that include cardiovascular endpoints or need to address treatment-related heart risk.